[HTML][HTML] Recent advances in therapeutic strategies for triple-negative breast cancer
Y Li, H Zhang, Y Merkher, L Chen, N Liu… - Journal of hematology & …, 2022 - Springer
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …
[HTML][HTML] Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Breast cancer is the second leading cause of death for women worldwide. The
heterogeneity of this disease presents a big challenge in its therapeutic management …
heterogeneity of this disease presents a big challenge in its therapeutic management …
[HTML][HTML] Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer
Background In an interim analysis of this phase 3 trial, the addition of pembrolizumab to
chemotherapy resulted in longer progression-free survival than chemotherapy alone among …
chemotherapy resulted in longer progression-free survival than chemotherapy alone among …
Treatment landscape of triple-negative breast cancer—expanded options, evolving needs
G Bianchini, C De Angelis, L Licata… - Nature reviews Clinical …, 2022 - nature.com
Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
[HTML][HTML] Breast cancer—epidemiology, classification, pathogenesis and treatment (review of literature)
B Smolarz, AZ Nowak, H Romanowicz - Cancers, 2022 - mdpi.com
Simple Summary Breast cancer is the most-commonly diagnosed malignant tumor in women
in the world, as well as the first cause of death from malignant tumors. The incidence of …
in the world, as well as the first cause of death from malignant tumors. The incidence of …
[HTML][HTML] Triple negative breast cancer: Pitfalls and progress
P Zagami, LA Carey - NPJ breast cancer, 2022 - nature.com
Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …
[HTML][HTML] ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆
Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
[HTML][HTML] Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
In triple-negative breast cancer (TNBC), the benefit of combining chemotherapy with
checkpoint inhibitors is still not very clear. We utilize single-cell RNA-and ATAC-sequencing …
checkpoint inhibitors is still not very clear. We utilize single-cell RNA-and ATAC-sequencing …
Breast cancer: an up‐to‐date review and future perspectives
R Hong, B Xu - Cancer communications, 2022 - Wiley Online Library
Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …
associated with many risk factors, including genetic and hereditary predisposition. Breast …
[HTML][HTML] First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival …
LA Emens, S Adams, CH Barrios, V Diéras, H Iwata… - Annals of …, 2021 - Elsevier
Background Guidelines recommend atezolizumab plus nab-paclitaxel (A+ nP) for first-line
treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer …
treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer …